Dynavax Technologies Corporation

Schering Corporation

Merck Sharp + Dohme Corp.

Other

Trisalus Life Sciences, Inc.

Medigen Vaccine Biologics Corporation

Surefire Medical, Inc.

Robert L Coffman

Cristiana Guiducci

Franck J Barrat

Radwan Kiwan

Gary S Ott

Stewart D Chipman

Richard Thomas Beresis

Robert S Janssen

Albert Frederick Candia, Iii

Edith M Hessel

Holger Kanzler

Robert J Milley

Robert A Kastelein

Tracy Matray

Andrew Evan Denker

Uyen Truong Phan

Svetlana Sadekova

Melissa A Kachura

David Ross Kaufman

Ying Yu

J Christopher Grimaldi

Samuel Zalipsky

Yu-Chi Wu

Donna M Rennick

Charles Chen

Maureen C Howard

Glen P Williams

Chung-Chin Wu

Yi-Jiun Lin

David Novack

John Darren Campbell

Jan Egbert De Vries

Fiona Powrie

Franck Barrat

Tsun-Yung Kuo

Meei-Yun Lin

Paula Traquina

Cristiana Auiducci

Edith Hessel

The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

Toll-like receptor antagonist compounds and methods of use

The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.

Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses. Also provided are methods of making pharmaceutical compositions containing these compounds. The present disclosure also describes methods of use for the alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, and pharmaceutical compositions containing these compounds for the treatment of disease in a subject.

Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.

Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer

The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I), and pharmaceutical compositions thereof, are antagonists of toll-like receptors such as TLR7, TLR8, and/or TLR9. In certain embodiments, compounds of the invention are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.

Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof

The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.

Branched chimeric compounds, and methods of use thereof

The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof. Additionally, the present disclosure provides polynucleotide Toll-like receptor 9 agonists with immune stimulatory and toxicity profiles suitable for intrapulmonary administration.

Administration of polynucleotide toll-like receptor 9 agonists for treating cancer

Linear chimeric compounds and methods of use thereof

Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof

Growing community of inventors

Portola Valley, CA, United States of America

Robert L Coffman